European Panel Recommends Against Adjuvant Sunitinib for High-Risk RCC

February 26, 2018 – The European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended against approving sunitinib for use as an adjuvant therapy in patients with renal cell carcinoma (RCC) who have received nephrectomy and are high risk for recurrence. The CHMP considered data from the phase III S-TRAC trial,1,2 in which adjuvant sunitinib prolonged disease-free survival (DFS) by 1.2 years compared with placebo … (leggi tutto)